A) RNA sequencing was performed on 2D-cultured primary human Hepatic Stellate Cells (HSC) genotyped for the PNPLA3 I148M variant.
B) RNA sequencing from liver biopsies of genotyped PNPLA3 patients, previously published (http:// dx. doi. org/ 10. 1136/gutjnl- 2019- 319226).
C) Comparison of both datasets of A and B.
D) Cell behaviour was evaluated in HSCs wild type (WT) or carrying I148M PNPLA3 cultured on 3D extracellular matrix (ECM) scaffolds from human healthy and cirrhotic liver with/without TGFB1 and NanoString was employed.